CF PHARMTECH: Bill Wenqing Liang Acquires Shares, Long Position Rises to 18.74%
HK Disclosure
Oct 02
On September 28, 2026, Bill Wenqing Liang bought 25,100 H-shares of CF PHARMTECH on the SEHK open market at an average of HKD 7.2916 per share, involving about HKD 183,019, an on-exchange active trade representing a direct secondary-market dealing. The purchase was made pursuant to an acting-in-concert agreement with Dr. LI LI BOVET.
Prior to the acquisition, Bill Wenqing Liang's long position in CF PHARMTECH was 60.67 million shares, representing 18.73%; following the acquisition, the holding changed to 60.70 million shares, with the long position ratio rising to 18.74%.
This involves related parties: Dr. LI LI BOVET, as per the acting-in-concert agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.